(SURMOUNT-1) Tirzepatide prescribing information (PI)
The adverse effects associated with this compounded medication primarily reflect those observed with semaglutide, as cyanocobalamin is generally well-tolerated with minimal side effects when administered at therapeutic doses
It highly depends on your health status, current medications, dosage, tolerance and drinking habits
However, semaglutide has FDA-approved uses under specific brand names and indications, while retatrutide remains investigational
Many patients find that they have less hunger and fewer cravings
Most clinicians would recommend maximizing results with a single agent before adding complexity, particularly given that tirzepatide already produces substantial fat loss on its own